Citius Oncology (CTOR) EBIT Margin (2025 - 2026)
Citius Oncology's EBIT Margin was -583.54% in fiscal Q3 2026 (quarter ended Jun 30, 2026), up 1132.63 percentage points from the prior quarter.
Powered by 
Analysis
Citius Oncology (CTOR) EBIT Margin (2025 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,134.96 Bn | 1,103.55 Bn | 19.71 Bn | 51.16% |
| 2 | Johnson & Johnson | 616.51 Bn | 535.04 Bn | 17.26 Bn | 28.21% |
| 3 | AbbVie | 501.10 Bn | 474.21 Bn | 12.70 Bn | 37.86% |
| 4 | Merck | 367.09 Bn | 321.47 Bn | 12.21 Bn | -3.52% |
| 5 | Novartis Ag | 298.10 Bn | 262.09 Bn | 11.24 Bn | 32.97% |
| 6 | Astrazeneca | 261.72 Bn | 235.40 Bn | 12.86 Bn | 20.57% |
| 7 | Amgen | 235.73 Bn | 191.13 Bn | 7.24 Bn | 34.95% |
| 8 | Gilead Sciences | 190.64 Bn | 164.84 Bn | 6.22 Bn | -133.21% |
| 9 | Pfizer | 169.63 Bn | 116.28 Bn | 10.94 Bn | 28.37% |
| 10 | Citius Oncology | 75.52 Mn | 45.11 Mn | 1.00 Mn | -583.54% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -583.54% |
| Mar 31, 2026 | -1,716.17% |
| Dec 31, 2025 | -133.17% |
API Access
Citius Oncology EBIT Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebit-margin&ticker=CTOR&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebit-margin", "ticker": "CTOR", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebit-margin&ticker=CTOR&period=max&api_key=YOUR_API_KEY");
const data = await res.json();